SG
VRPX

StoneX Group’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

StoneX Group’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-46
Closed -$7.22K – 728
2022
Q4 		$7.22K Buy
+46
New +$10.5K ﹤0.01% 473

Other funds holding VRPX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return

StoneX Group's VRPX Position: Q1 2023 in Review

StoneX Group sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2023, closing a stake of 46 shares — an estimated $7.22K sold.

StoneX Group first reported a position in VRPX in Q4 2022 and held it in 1 quarter. The position peaked at $7.22K in Q4 2022. 14 funds tracked by Wall St. Rank hold VRPX as of Q1 2023.

  • StoneX Group reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • StoneX Group sold 46 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $7.22K.
  • StoneX Group first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • StoneX Group's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $7.22K in Q4 2022.
  • 14 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.